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Abstract 
Aims: ‘Tr iphala’ constituting equal par ts of three medicinal dr ied plant fruits Emblica Officinalis Gaer tn., 
Terminalia chebula Retz. and Terminalia bellerica Gaertn. is an antioxidant rich Ayurvedic formulation. The pre-
sent study assessed therapeutic as well as protective effects of Triphala on human subjects with Type 2 diabetes 
mellitus (T2DM) and Impaired glucose tolerance (IGT).   
Materials and methods: Tr iphala at a dose of 5 gms BD was administered to two cohorts viz., IGT, N= 20 
and T2DM, N=30 consecutively for a period of 12 months. The therapeutic efficacy was assessed quarterly by 
monitoring blood glucose and lipid levels; the protective effect by monitoring antioxidants level quarterly and 
DNA damage annually. Toxicity if any, to liver and kidney due to long term administration was assessed quarterly 
in both cohorts.  
Results: Continuous ‘Tr iphala’ therapy for  12 months significantly reduced blood glucose (p≤0.001) and li-
pid levels (p≤0.05) in both the cohorts. Triphala resisted oxidative stress generated during the course of hypergly-
cemia by significantly increasing the activity of super oxide dismutase and Catalase (p≤0.001) and the level of re-
duced glutathione (p≤0.001). Protective effect on DNA was accessed through significant reduction in the comet tail 
length (p≤0.001). 
Conclusions: ‘Triphala’ ameliorated not only the oxidative stress but also normalized glucose and lipid homeosta-
sis in subjects with impaired glucose and T2DM. 
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Introduction 
 Type 2 Diabetes mellitus (T2DM) is characterised 
as a metabolic disorder as it alters both glucose and lipid 
homeostasis (1, 2). Globally, diabetic population 
outnumber owing to high degree of genetic 
predisposition and physical inactivity, characterised by 
high abdominal adiposity, body fat percentage and level 
of insulin resistance (3, 4). The most common 
alterations in lipid profile in T2DM involve an elevation 
in plasma triglyceride (TG) and Low density lipoprotein 
cholesterol (LDL-C) concentrations, and low levels of 
High density lipoprotein cholesterol (HDL-C) (5, 6, 7). 
Hypertriglyceridemia contributes significantly to the 
increased risk for premature cardiovascular disease in 
T2DM (8). Perturbed glucose and lipid homeostasis are 
manifested as oxidative stress in the insulin dependent as 
well as insulin independent tissues (9). Development of 
impaired glucose tolerance (IGT) is the outcome of the 
cumulative effect of all above mentioned disparities and 
worsened into the form of fully developed T2DM.  
Diabetes Control and Complications Trial (DCCT) and 
the United Kingdom Prospective Diabetes Study 
(UKPDS) have demonstrated improved outcomes with 
early detection and tight control of blood glucose (10, 
11). Diabetes Epidemiology: Collaborative analysis of 
Diagnostic criteria in Europe (DECODE) stated that 
subjects with IGT have an increased risk for developing 
T2DM and cardiovascular complications and therefore 
form an important high-risk group for actions aimed at 
preventing T2DM (12).  
 According to WHO, traditional herbal remedies 
may provide valuable leads for the development of 
alternative drugs and strategies for T2DM and its related 
complications (13). Herbs prove good antidiabetic 
agents as they not only improve glucose and lipid 
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metabolism by stimulating insulin release; attenuating 
the absorption of carbohydrates from the gut but also 
improve antioxidant status. ‘Triphala’ is the most 
commonly used Indian Ayurvedic herbal formulation of 
the "Rasayana" group, consisting equal parts of three 
medicinal dried plant fruits Emblica Officinalis Gaertn., 
Terminalia chebula Retz. and Terminalia bellerica 
Gaertn. (14). Triphala is reported to exhibit a variety of 
biological activities, such as anti-cancer, anti-
mutagenic, anti-viral, anti-oxidant and free radical 
scavenging activities and is reported to be reno- and 
hepato-protective (15, 16). Triphala and its individual 
components have been shown to prevent hyperglycemia 
and diabetic cataract (17, 18). The present study 
evaluated the therapeutic potential of ‘Triphala’ in 
human subjects with IGT and T2DM.   
 
Materials and Methods 
Study design and Participants  
This was a unicentre, randomized and prospective 
study comparing two different modalities, IGT and 
T2DM subjects. The study was conducted in diabetes 
clinic run by School of Studies in Biochemistry, Jiwaji 
University, Gwalior, India, on every sunday under the 
supervision of an Ayurvedic physician. About 500 
T2DM and IGT subjects are registered and regularly 
attend the camp for monthly check up and follow up. 
The study was approved by the human ethical 
committee board of Jiwaji University Gwalior. The 
study protocol was approved by AYUSH and 
Institutional Human Ethics Committee.  
Selection criteria for the study included the 
following for the people with T2DM and IGT; age >40 
years, not on any antihyperglycemic or antioxidant 
therapy, not taking any lipid lowering therapy. A total 
of 50 subjects attending the diabetes clinic were selected 
and registered for the study after monitoring their 
glycemic status and were categorised to one of the two 
modalities viz., IGT subjects (FBG: 110-126 mg/dl and 
PPBG: ≥140 mg/dl to ≤200 mg/dl, N= 20) and T2DM 
(FBG: ≥126mg/dl and PBG: ≥200mg/dl, N= 30) with 
poor glycemic control based on the criteria for the 
diagnosis of T2DM and IGT by the WHO. The mean 
age of the subjects was 54.3±1.75 years in T2DM group 
and 55.1±2.02 years in IGT group. The duration of 
diabetes was 4.4±0.58 years for T2DM subjects and 
3.8±0.66 years for IGT subjects. All the subjects were 
informed of the objectives of the study prior to 
registration and were asked to give a written informed 
consent. Other demographic and clinical characteristics 
of the participating subjects are given in Table 1. 
Subjects suffering from any chronic or acute 
inflammatory illness were excluded from the study.  
 
Preparation of Triphala composition 
Fresh mature fruits of Emblica Officinalis 
Gaertn. were purchased from local market in the 
Gwalior and shade dried. Whole dried fruit of 
Terminalia chebula Retz. and Terminalia bellerica 
Gaertn. were purchased from the local market in the 
Gwalior. The dried fruits were then separately milled to 
fine powder; the powder of individual components was 
further mixed in the equal proportion to get the Triphala 
composition. 
 
Administration of ‘Triphala’ 
The registered T2DM and IGT subjects were 
enrolled under Triphala therapy at a dose of 5 gms BD 
before meal (30 minutes prior) every day with normal 
water for a period of 12 months. Triphala powder was 
packaged in the airtight sealed plastic bags and each 
packet contained 35 gms Triphala powder (5 gms BD 
for 7 days) for the first three months. After three months 
of weekly follow up, sincere and regular patients were 
then continued for the next nine months of study and 
each packet contained 150 gms of Triphala powder (5 
gms BD for 30 days) till the study end; medicine did not 
change during the study period. The participants were 
provided regular counselling on causes and management 
of diabetes besides anti diabetic ayurvedic medicines. 
None of the study subjects were on antioxidant 
supplementation or lipid lowering or anti-diabetic drugs 
while taking Triphala. The subjects were advocated to 
maintain their moderate physical activity and to avoid 
carbohydrate rich diet during the study period. The 
subjects were followed up at regular monthly intervals 
for up to 12 months. The therapeutic efficacy of 
‘Triphala’ was evaluated by monitoring glycemic 
control and plasma lipid profile at specific intervals 
during the course of study. 
 
Anthropometric data collection and measurement 
methods 
Details of ethnic origin and age were directly 
ascertained from the subjects; waist (cm), at the level of 
the umbilicus with the patient standing and breathing 
normally, while weight (kg) with weighing balance and 
height (m), with scale and metal rule, were measured (in 
light clothing, without shoes). After 10 minutes rest, 
systolic (first phase) and diastolic (fifth phase) blood 
pressures (sBP, dBP) were taken on the dominant arm in 
a sitting position, using a standard mercury gauge 
sphygmomanometer.  
 
Collection of blood samples 
Approximately 2.5 ml of venous blood was 
collected in the morning after 12 hours fast from each 
subject under study once in the beginning of the study 
and at monthly intervals during the course of study 
period. Fasting blood samples were transferred to 
sterilized centrifuge tubes containing sodium EDTA/ 
sodium fluoride (for glucose) and allowed to stand for 
10 minutes at room temperature and then centrifuged 
(5000 rpm x 10 min x 4oc) to get clear plasma. Plasma 
samples were stored at -20oC for later analysis. After 
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removal of plasma and buffy coat from the whole blood; 
the red blood cells were suspended in 2 ml normal saline 
and centrifuged (3000 rpm x 10 min x 4oC) to get cell 
pellet. The cell pellet was washed thrice with normal 
saline to get packed cell volume (PCV). Haemolysate 
was prepared by mixing 1.9 ml of cold distilled water to 
0.1 ml of PCV suspension and stored at 4˚C. 
 
Laboratory methods  
Blood glucose concentrations in fasting and 
postprandial samples were determined by the glucose 
oxidase and peroxidase method using a commercial kit 
(Erba diagnostics glucose kit, Mannheim Germany) in 
the fresh blood samples at monthly intervals. 
Glycosylated Hemoglobin was measured from fresh 
blood at 3 monthly intervals by ion exchange resin 
method. The key lipid profile markers viz. total serum 
cholesterol (TC) (Cholesterol oxidase- peroxidase 
method), serum triglyceride (TG) (Glycerol 3 
peroxidase method), Serum High Density Lipoprotein 
Cholesterol (HDL-C) (Polyethylene Glycol Precipitation 
method), Low Density Lipoprotein Cholesterol (LDL-C) 
(Freidewald’s Formula) and Very Low Density 
Cholesterol (VLDL-C) (Freidewald’s Formula) were 
assayed using commercial kits ( Ecoline Merck NJ 
USA) from stored plasma at 4 monthly intervals. 
Analysis of liver function markers viz., Serum aspartate 
aminotransferase (AST), Alanine amino transferase 
(ALT) by Modified International federation of clinical 
chemistry method and serum Bilirubin by Modified 
Jendrassik and Grof’s method at 4 monthly intervals 
from stored plasma. Kidney function markers viz., Urea 
by Glutamate Dehydrogenase kinetic method, uric acid 
by Uricase Method and creatinine by Alkaline Picrate 
Method were analyzed in serum samples at 4 monthly 
intervals from stored plasma. Oxidative stress markers 
viz., Superoxide dismutase activity and Catalase activity 
were analysed at 4 monthly intervals from the 
hemolysate (19, 20). Lipid peroxidation and reduced 
glutathione were estimated by from fresh whole blood. 
Protein was estimated by the method of Lowry et al (21, 
22). 
 
Statistical analysis 
The sample size of at least 20 participants per 
group provided adequate power to detect a difference. 
Statistical analysis was performed using one-way 
ANOVA and comparison of the data was done by 
Student-Newman-Keuls Method with all pair-wise 
multiple comparison procedures. The data were 
expressed as Mean ± SE. The level of significance was 
set at p ≤0.05.  
 
Results 
Baseline characteristics 
 Table 1 shows the baseline characteristics of the 
50 subjects enrolled in the study which includes 30 
T2DM and 20 IGT subjects. FBG and PPBG were 
significantly higher in T2DM compared to IGT subjects 
(p≤0.05). In addition systolic blood pressure was 
significantly higher in T2DM subjects (p≤0.05).  
 
Table 1: Baseline characteristic features of subjects 
with IGT and T2DM  
Results: mean values (± S.E.M); IGT: Impaired glucose 
tolerance; T2DM: Type 2 diabetes mellitus.  
 
Glucose metabolism 
 Blood glucose, HbA1c variables for month 0, 4, 8 
and 12 for both the treatment groups are shown in Table 
2. Individual group analysis revealed that the baseline 
FBG and PPBG value were significantly higher in the 
T2DM compared to the IGT subjects (p≤0.001). 
Triphala therapy significantly reduced the glucose levels 
in the circulation however in T2DM subjects the 
reduction in PPBG levels 29.0% (p≤0.001) was more 
pronounced compared to the FBG 20.9% (p≤0.001) by 
12th month; however, 50% and 57% of this decrease 
occurred by 4th month in both PPBG and FBG 
respectively. Similarly, in subjects with IGT the FBG 
and PPBG levels were significantly reduced by 23.5% 
(p≤0.001) and 22.3% (p≤0.001) by 12th month of 
Triphala therapy however 57% and 64% of this 
reduction occurred from 4th month onwards in FBG and 
PPBG respectively. Glycemic level did not affect the 
blood glucose lowering potential of Triphala as drawn 
out from the significant reductions in FBG and PPBG in 
both T2DM and IGT groups from 4th month onwards. 
GHb levels showed 22.7% (p≤0.001) and 18.1% 
(p≤0.001) reduction in T2DM and IGT subjects; 
however, 41% and 43% of this decrease occurred from 
4th month onwards indicating that short term 
administration of Triphala showed good glycemic 
control in T2DM and IGT subjects respectively.  
Features IGT T2DM 
Number 20 30 
Age (years) 55.1±2.02 54.3±1.75 
Sex (male/female) 16/4 28/2 
Weight in (Kg) 67.8±2.03 71.2±2.09 
Body mass index BMI 
(kg/m2) 
24.8±0.46 25.6±0.55 
Fasting blood glucose 
(mg/dl) 
124.5 ±0.6 172.3±6.6 
PP blood glucose  
(mg/dl) 
168.9 ±4.18 272.3±11.4 
Systolic blood pressure 
(mm Hg) 
137.6±3.21 141.6±3.17 
Diastolic blood pressure 
(mm Hg) 
80.4±2.58 81.6±0.99 
Duration of disease 
(years) 
3.8±0.66 4.4±0.58 
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Table 2: Effect of 12 months of Triphala therapy on 
blood glucose and HbA1c in subjects with T2DM and 
IGT. 
Values are mean ±SE; ap£0·001, bp£0·01, cp£0·05 are 
significantly different from baseline value (0 month) by 
one way ANOVA. 
 
Lipid metabolism 
 Analysis of individual group reveals glycemic 
control was associated with a significant improvement 
in plasma lipid profile. Fasting plasma TG, TC, LDL-C, 
levels were significantly higher in T2DM patients than 
in IGT group and consumption of Triphala led to 
significant and time dependent improvement (Table 3). 
By 12th month atherogenic lipids such as TC and LDL-C 
were significantly reduced by 23.1% (p≤0.001) and 
27.4% (p≤0.001) respectively in T2DM subjects; 
however 28.3% and 27.4% of this reduction was 
observed by 4th month, indicative of effectiveness of 
long term administration of Triphala in the management 
atherogenic lipids in subjects with T2DM. By 12th 
month subjects with IGT showed 21% (p≤0.001) and 
36.2% (p≤0.001) reduction in TC and LDL-C levels; 
however, 54% and 50% decrease of this value was 
observed in 4th month, indicative of effectiveness of 
short term administration of Triphala in subjects with 
IGT. HDL-C is significantly increased by 21.1% 
(p≤0.05) and 20.2% (p≤0.05) in T2DM and IGT group; 
however, 32% and 31% of this increase was observed in 
4th month. The total population of T2DM and IGT on 
Triphala displayed a marked reduction in the mean total 
plasma TG by 25.9% (p≤0.05) and 22.1% (p≤0.05) in 12 
months; however, 29.4% and 32% of this decrease was 
observed in 4th month. The data indicates that long term 
Triphala therapy was beneficial for both IGT and 
T2DM.  
Variable(s) Intervals 
(months) 
IGT  (n=20) T2DM (n=30) 
FBG  
(mg/dl)       
0 124.5 ±0.6 172.3±6.6 
4 107.9±4.21b 151.7±6.5c 
8 107.2±4.22b 148.0±5.3c 
12 95.2±1.79a 136.2±5.2a 
P.P BG  
(mg/dl)       
0 168.9 ±4.18 272.3±11.4 
4 144.5±5.49b 232.8±12.0c 
8 137.9±5.98a 214.5±8.2c 
12 131.2±4.95a 193.3±8.0a 
0 6.5±0.22 9.6±0.35 HbA1c  
(%)       
4 6.0±0.22 8.7±0.35c 
8 5.6±0.20b 8.3±0.39c 
12 5.4±0.21a 7.4±0.33a 
Table 3: Effect of Triphala therapy on Lipid profile 
in subjects with T2DM and IGT.  
Values are mean ±SE; ap£0·001, bp£ 0·01, cp£0·05 are 
significantly different from baseline value (0 month) by 
one way ANOVA. 
 
Alleviation of Oxidative stress 
 The activity of antioxidant enzymes viz., SOD and 
CAT were significantly increased by 31.3% (p≤0.001) 
and 34.2% (p≤0.001) in T2DM subject; however, 30.4% 
and 45.6% of this increase was observed in 4th month of 
Triphala therapy. IGT subjects showed 33.6% (p≤0.001) 
and 37% (p≤0.001) increase in the activity of SOD and 
CAT in 12 months however 31% and 40% of this 
increase was observed in 4th month respectively. By 12th 
month the level of GSH was increased significantly in 
both T2M and IGT subjects by 34.5% (p≤0.001) and 
33.7% (p≤0.001) respectively, by 4th month 33.7% of 
this increase was observed in both T2DM and IGT 
subjects. TBARS levels were significantly reduced by 
25.5% (p≤0.001) and 30% (p≤0.01) in T2DM and IGT 
subjects respectively by 12th month, however 26% and 
28% of this decrease was observed in 4th month of 
Triphala therapy. Triphala therapy retrieved the 
oxidative damage of DNA quantitatively as evident from 
the significant reductions in the comet tail length by 
Variable(s) Intervals 
(months) 
IGT  (n=20) T2DM 
(n=30) 
TC  
(mg/dl)       
0 174.7 ±4.65 191.8±6.84 
4 155.0±5.34b 179.3±6.60 
8 149.7±4.25b 160.4±5.27a 
12 138.0±5.41a 147.4±5.35a 
TG  
(mg/dl)       
0 141.0 ±9.76 158.9±10.71 
4 130.9±9.63 146.7±10.68 
8 114.6±9.45c 133.3±10.94c 
12 109.7±9.00c 117.6±10.18c 
HDL-C 
(mg/dl)       
0 36.7 ±2.59 35.8±2.24 
4 39.0±2.76 37.2±2.36 
8 41.8±3.02 38.5±2.09 
12 46.1±2.70c 44.6±2.0c 
LDL-C  
(mg/dl)       
0 109.7 ±5.59 125.2±6.67 
4 89.7±6.53c 112.7±6.25 
8 84.9±5.34b 95.2±4.81a 
12 69.9±5.79a 79.6±4.85a 
0 28.2 ±1.95 31.7±2.14 VLDL-C 
(mg/dl)       
4 26.2±1.92 29.3±2.13 
8 22.9±1.89c 26.6±2.18c 
12 21.9±1.80c 23.5±2.03c 
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21.1% (p£0·005) in T2DM and 26% (p£0·001) in IGT 
subjects respectively. Hence the results indicate that 
short term administration of an antioxidant rich natural 
therapy like Triphala can significantly improve the 
antioxidant status. 
 
Table 4: Effect of Triphala therapy on oxidative 
stress markers markers.  
Values are mean ±SE; ap£0·001, bp£ 0·01, cp£0·05 are 
significantly different from baseline value (0 month) by 
one way ANOVA. 
 
Table 5: Effect of Triphala therapy on oxidative 
DNA damage after 12 months 
Values are mean ±SE; ap£0·001, bp£ 0·01, cp£0·05 are 
significantly different from baseline value (0 month) by 
one way ANOVA.  
 
Variable(s) Intervals 
(months) 
IGT 
(n=20) 
T2DM 
(n=30) 
Superoxide 
Dismutase 
(SOD) 
(Unit/min/
mg of 
protein)     
0 0.83±0.04 0.76 ±0.02 
4 0.91±0.04 0.84±0.03
c 
8 1.10±0.05
a 0.97±0.05c 
12 1.25±0.05
a 1.11±0.06a 
Catalase 
(CAT) 
(μmole/min/
mg 
protein)     
0 6.7±0.32 6.5 ±0.19 
4 7.7±0.34
c 7.5±0.26c 
8 9.2±0.45
b 8.2±0.39a 
12 
10.6±0.26a
  
9.8±0.36a 
Reduced 
glutathione 
(GSH) (mg/
ml)     
0 1.9±0.13 1.8 ±0.11 
4 2.2±0.18
c 2.0±0.15 
8 2.6±0.21
c 2.5±0.15b 
12 3.1±0.1
a 2.8±0.12a 
0 368.5±22.02 451.5 ±18.04 Thio-
barbeturic 
acid reactive 
substance 
(TBARS) 
(moles of 
MDA / ml 
blood)     
4 337.0±23.11
c 421.3±16.48 
8 
301.1±21.19c 371.1±16.27b 
12 
257.7±16.99b 336.1±16.27a 
Variable(s) Intervals IGT 
(n=20) 
T2DM 
(n=30) 
0 month 4.6±1.6 5.2 ±1.1 Comet tail 
length 
(arbitrary unit) 
12 months 3.4±1.02b 4.1±1.07a 
Figure 1: Assessment of DNA damage through 
alkaline comet assay in Triphala administered subjects. 
Ethedium bromide stained representative pseudo colored 
images are shown for IGT (A) and T2DM (C) 
respectively before Triphala Regimen. Intense red color 
represents intact DNA, while blurred tail like structure 
shows increasing level of DNA fragmentation. Images 
(B) are (D) are captured under identical magnification 
(10x) to show the relative recovery after Triphala 
therapy respectively. 
 
 
Antitoxic effect on Liver and kidney 
 The liver function markers viz., Bilirubin, SGOT 
and SGPT were significantly reduced by 22.2% 
(p≤0.001), 22.1% (p≤0.05) and 29% (p≤0.01) 
respectively in T2DM subjects, similarly IGT subjects 
showed 25% (p≤0.001), 24% (p≤0.05) and 28% (p≤0.01) 
reduction in the following liver function markers 
respectively.  
 Kidney function markers viz., creatinine, urea and 
uric acid were significantly reduced by 27% (p≤0.001), 
29% (p≤0.001) and 24% (p≤0.001) in T2DM subjects. 
Similarly, IGT subjects showed significant reduction of 
24% (p≤0.01), 25% (p≤0.001) and 26% (p≤0.001) 
respectively in 12 months of Triphala therapy. Results 
indicated antitoxic effect of long term administration of 
Triphala on liver and kidney. 
 
Table 6: Effect of Triphala therapy on Liver and 
kidney function markers.  
Variable(s) 
Intervals 
(months) 
IGT (n=20) 
T2DM 
(n=30) 
AST  
(U/I)       
0 27.2±1.83 26.6 ±1.46 
4 25.0±1.69 22.9±1.73c 
8 23.1±1.90 24.1±1.66c 
12 20.7±1.76c 20.7±1.42c 
ALT  
(U/I)       
0 26.4±1.63 28.4 ±1.42 
4 24.1±1.45c 23.4±1.60c 
8 22.5±1.51c 22.8±1.60c 
12 18.9±1.33b 20.1±1.10b 
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Values are mean ±SE; ap £0·001, bp £ 0·01, cp £0·05 are 
significantly different from baseline value (0 month) by 
one way ANOVA. 
 
Discussion  
Diabetes mellitus is the World's largest growing 
metabolic disorder, goes un-noticed in the form of 
prediabetics (IGT), presenting all the aetiologies of 
T2DM, thus forms a major risk group aimed at 
preventing T2DM. Traditional plant medicines are 
being used in place of costlier modern medicines 
throughout the world for better management of T2DM 
and IGT (23). Thus in the present study antioxidant rich 
ayurvedic formulation Triphala was validated for its 
antihyperglycemic, antihyperlipidemic and antioxidant 
potential in human T2DM and IGT subjects.  
Oral administration of Triphala to humans 
T2DM and IGT subjects for 12 months resulted in a 
significant reduction in both FBG and PPBG levels 
however; the reduction in PPBG was more pronounced 
compared to FBG in IGT groups. The improvement in 
glycemic levels of IGT group due to Triphala can help 
control the progression of T2DM. Treatment with 
Triphala significantly decreased the levels glycosylated 
haemoglobin. The proportion of haemoglobin that is 
glycosylated is known to increase substantially in 
conditions of sustained hyperglycaemia (24, 25). The 
significant reduction in glycemic level with Triphala 
could be due to the optimization of activities of 
carbohydrate metabolizing enzymes, increase in 
carbohydrate absorption time and stimulation of insulin 
release from the pancreatic beta cells (26, 27). Glucose 
lowering effects of Triphala have been reported earlier 
in STZ induced diabetic rats (27, 28, 29). 
Bilirubin 
(mg/dl)       
0 0.8±0.03 0.96±0.03 
4 0.75±0.03 0.81±0.02a 
8 0.66±0.03c 0.76±0.03a 
12 0.6±0.03a 0.75±0.03a 
Urea  
(mg/dl)       
0 33.3±1.12 35.2 ±1.15 
4 30.0±1.46 30.7±1.01b 
8 28.3±1.46c 29.9±1.07b 
12 24.9±1.06a 25.0±1.02a 
Uric acid 
(mg/dl)       
0 5.3±0.21 5.4 ±0.17 
4 4.6±0.17c 4.8±0.16c 
8 4.2±0.17a 4.4±0.14b 
12 3.9±0.16a 4.1±0.16a 
Createnine 
(mg/dl)       
0 1.04±0.06 1.09 ±0.04 
4 0.96±0.05 0.95±0.04c 
8 0.93±0.04 0.91±0.04c 
12 0.79±0.04b 0.79±0.04a 
The American Heart Association emphasizes the 
role of lipid abnormalities in T2DM (30, 31). In the 
present study dyslipiemia was recorded in both T2DM 
and IGT though the increase in triglycerides (TG) and 
low-density lipoprotein cholesterol (LDL-C) levels and 
decrease high-density lipoprotein cholesterol (HDL-C) 
was more in T2DM. We observed the percentage 
improvement in lipid profile owing to Triphala was 
statistically significant in both IGT and T2DM subjects. 
Both treatment groups with reduction in levels of plasma 
TG and TC displayed a significant increase in the levels 
of the HDL fraction on Triphala therapy. The decreased 
serum HDL-C was reversed towards normalization after 
Triphala therapy. The beneficial effect of Triphala on 
HDL–C is well recognised and likely to be clinically 
relevant. The progressive shift of LDL profile towards 
normal with decrease in fasting TG and TC levels 
observed in T2DM resulted perhaps from a specific 
decrease in plasma levels of glucose fractions by 
Triphala. The blood glucose and lipid lowering activity 
of Triphala demonstrated in IGT subjects in this study 
may represent a novel and important preventive 
approach in delaying the onset of diabetes mellitus and 
CVD; however the long term administration of Triphala 
proved effective in addressing dyslipidemia. The blood 
lipid lowering effects of Triphala are attributed to 
Terminalia chebula Retz. (32, 33) 
Results of the present study indicated that 
Triphala besides antihyperglycemic, antihyperlipidemic 
possesses a very good antioxidant property. Triphala 
administration attenuated the diabetes induced depletion 
of antioxidants. Triphala not only significantly increased 
the activity of antioxidant enzymes viz., SOD and CAT 
but also increased the levels of reduced glutathione in 
both the treatment groups. The observed improvement in 
the level of these antioxidants after the administration of 
Triphala in hyperglycemia may be due to the direct 
reaction of gallic acid, ascorbic acid and flavonoids in 
Triphala with the free radicals generated and converting 
the reactive oxygen free radicals to non-reactive 
products (34, 35). Lipid peroxidation is regarded as one 
of the basic mechanism of tissue damage caused by free 
radicals. Triphala administration significantly reduced 
the levels of LPO in both T2DM and IGT groups. This 
scrutiny reveals that Triphala is able to quench the LPO 
chain and is capable to shield the membrane from free 
radical caused injuries. Triphala therapy significantly 
protected the DNA from oxidative damage in both 
T2DM and IGT subjects. This present study thus 
indicates the antioxidant potency of the drug. 
To conclude, the results of the present study have 
empirically indicated that Triphala has protective role in 
IGT and was effective in the treatment of T2DM. A 
consistent decrease in the blood glucose level by 
Triphala in diabetic patients and parallel improvement in 
lipid profile makes it a good choice as an alternative 
antidiabetic drug which is non habit forming and cheap 
as alternatives are needed due to side effects of several 
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allopathic drugs and development of resistance to 
currently used.  
 There are clearly some limitations of this study. 
First, this is an ancillary study that is dependent on the 
main study for the study design. Second the number of 
patients in each group is small. Though the study was 
powered for antihyperglycemic potential of the drug 
under observation, a very important parameter i.e. 
measurement of insulin release is lacking.  
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